Plunkett Research Online: Mineralys Therapeutics Inc

MINERALYS THERAPEUTICS INC (MLYS:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that .....



Mineralys Therapeutics Inc
Ticker: MLYS
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 888 378-6240
Fax:
Address: 150 North Radnor Chester Road
Suite F200
Radnor, PA 19087 United States

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Biotechnology
Biotechnology
Healthcare

Ranks not available
Contacts Description
Jon CongletonCEO/Director
Adam LevyCFO/Secretary
See More
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that .....See More See More

Auditor: EY
Legal Advisor:
$USD, In whole numbers,
except marked * or %
2023202220212020
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
NameTitleSalary (US$)Bonus (US$)
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: